Sight Sciences, Inc. NASDAQ:SGHT

Founder-led company

Sight Sciences stock price today

$4.09
+0.52
+14.57%
Financial Health
0
1
2
3
4
5
6
7
8
9

Sight Sciences stock price monthly change

-53.09%
month

Sight Sciences stock price quarterly change

-53.09%
quarter

Sight Sciences stock price yearly change

-39.08%
year

Sight Sciences key metrics

Market Cap
178.14M
Enterprise value
278.47M
P/E
-5.14
EV/Sales
2.69
EV/EBITDA
-2.21
Price/Sales
4.15
Price/Book
2.68
PEG ratio
-0.21
EPS
-1.12
Revenue
81.49M
EBITDA
-50.37M
Income
-54.74M
Revenue Q/Q
2.34%
Revenue Y/Y
8.26%
Profit margin
-128.91%
Oper. margin
-124.72%
Gross margin
82.47%
EBIT margin
-124.72%
EBITDA margin
-61.81%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Sight Sciences stock price history

Sight Sciences stock forecast

Sight Sciences financial statements

Average Price Target
Last Year

$8.33

Potential upside: 103.74%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Sight Sciences, Inc. (NASDAQ:SGHT): Profit margin
Jun 2023 23.47M -14.75M -62.86%
Sep 2023 20.00M -13.03M -65.15%
Dec 2023 18.75M -10.69M -57.02%
Mar 2024 19.26M -16.26M -84.43%
Sight Sciences, Inc. (NASDAQ:SGHT): Debt to assets
Jun 2023 185289000 49.15M 26.53%
Sep 2023 176641000 49.57M 28.06%
Dec 2023 166651000 46.43M 27.86%
Mar 2024 155560000 46.35M 29.8%
Sight Sciences, Inc. (NASDAQ:SGHT): Cash Flow
Jun 2023 -13.48M -97K 766K
Sep 2023 -9.82M -304K 118K
Dec 2023 -6.48M -264K 376K
Mar 2024 -9.78M -117K -942K

Sight Sciences alternative data

Sight Sciences, Inc. (NASDAQ:SGHT): Employee count
Aug 2023 250
Sep 2023 250
Oct 2023 250
Nov 2023 250
Dec 2023 250
Jan 2024 250
Feb 2024 250
Mar 2024 214
Apr 2024 214
May 2024 214
Jun 2024 214
Jul 2024 214

Sight Sciences other data

49.58% -3.84%
of SGHT is owned by hedge funds
23.65M -1.75M
shares is hold by hedge funds

Sight Sciences, Inc. (NASDAQ:SGHT): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 29312
Apr 2024 0 34129
May 2024 0 13066
Jul 2024 0 34774
Oct 2024 0 118327
Nov 2024 558426 551802
Dec 2024 8376 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
RAHEJA MANOHAR K. officer: EVP, Research & Develo..
Common Stock 5,000 $3.85 $19,250
Purchase
RAHEJA MANOHAR K. officer: EVP, Research & Develo..
Common Stock 3,376 $3.89 $13,133
Purchase
RAHEJA MANOHAR K. officer: EVP, Research & Develo..
Common Stock 4,624 $3.99 $18,441
Purchase
ENCRANTZ STAFFAN director, 10 percent owner:
Common Stock 551,802 $3.73 $2,058,221
Sale
ENCRANTZ STAFFAN director, 10 percent owner:
Common Stock 551,802 $3.73 $2,058,221
Purchase
RAHEJA MANOHAR K. officer: EVP, Research & Develo..
Common Stock 2,000 $3.7 $7,400
Sale
LINK MATTHEW officer: Chief Commercial Officer
Common Stock 21,831 $5.61 $122,450
Sale
LINK MATTHEW officer: Chief Commercial Officer
Common Stock 20,487 $5.98 $122,451
Sale
LINK MATTHEW officer: Chief Commercial Officer
Common Stock 20,970 $5.84 $122,444
Sale
LINK MATTHEW officer: Chief Commercial Officer
Common Stock 20,734 $5.91 $122,434
Patent
Application
Filling date: 27 May 2022 Issue date: 8 Sep 2022
Grant
Filling date: 16 Dec 2021 Issue date: 19 Jul 2022
Grant
Filling date: 15 May 2019 Issue date: 19 Jul 2022
Application
Filling date: 16 Feb 2022 Issue date: 2 Jun 2022
Grant
Filling date: 23 Apr 2021 Issue date: 31 May 2022
Application
Filling date: 23 Nov 2021 Issue date: 26 May 2022
Application
Filling date: 23 Nov 2021 Issue date: 26 May 2022
Application
Filling date: 16 Dec 2021 Issue date: 7 Apr 2022
Application
Filling date: 16 Dec 2021 Issue date: 7 Apr 2022
Grant
Filling date: 9 Dec 2016 Issue date: 29 Mar 2022
Insider Compensation
Mr. Paul Badawi (1975) Co-Founder, Pres, Chief Executive Officer & Director $496,710
Mr. Sam Boong Park (1961) Chief Operating Officer
$422,950
Mr. Shawn O'Neil (1973) Chief Commercial Officer
$413,930
Thursday, 19 December 2024
globenewswire.com
Tuesday, 19 November 2024
globenewswire.com
Saturday, 9 November 2024
seekingalpha.com
Thursday, 7 November 2024
zacks.com
Thursday, 17 October 2024
globenewswire.com
Monday, 14 October 2024
globenewswire.com
Tuesday, 20 August 2024
globenewswire.com
Saturday, 3 August 2024
seekingalpha.com
Thursday, 1 August 2024
zacks.com
Thursday, 18 July 2024
globenewswire.com
Monday, 10 June 2024
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
globenewswire.com
Sunday, 5 May 2024
Seeking Alpha
Thursday, 2 May 2024
Zacks Investment Research
Thursday, 18 April 2024
GlobeNewsWire
Tuesday, 26 March 2024
GlobeNewsWire
Thursday, 7 March 2024
Seeking Alpha
Zacks Investment Research
Thursday, 22 February 2024
GlobeNewsWire
Wednesday, 21 February 2024
Zacks Investment Research
Monday, 13 November 2023
InvestorPlace
Saturday, 11 November 2023
Seeking Alpha
Tuesday, 24 October 2023
GlobeNewsWire
Thursday, 21 September 2023
Benzinga
Tuesday, 12 September 2023
Market Watch
Wednesday, 30 August 2023
GlobeNewsWire
Monday, 7 August 2023
Seeking Alpha
Sunday, 6 August 2023
Seeking Alpha
Thursday, 3 August 2023
Zacks Investment Research
  • What's the price of Sight Sciences stock today?

    One share of Sight Sciences stock can currently be purchased for approximately $4.09.

  • When is Sight Sciences's next earnings date?

    Unfortunately, Sight Sciences's (SGHT) next earnings date is currently unknown.

  • Does Sight Sciences pay dividends?

    No, Sight Sciences does not pay dividends.

  • How much money does Sight Sciences make?

    Sight Sciences has a market capitalization of 178.14M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.63% to 81.06M US dollars.

  • What is Sight Sciences's stock symbol?

    Sight Sciences, Inc. is traded on the NASDAQ under the ticker symbol "SGHT".

  • What is Sight Sciences's primary industry?

    Company operates in the Healthcare sector and Medical - Devices industry.

  • How do i buy shares of Sight Sciences?

    Shares of Sight Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Sight Sciences's key executives?

    Sight Sciences's management team includes the following people:

    • Mr. Paul Badawi Co-Founder, Pres, Chief Executive Officer & Director(age: 50, pay: $496,710)
    • Mr. Sam Boong Park Chief Operating Officer(age: 64, pay: $422,950)
    • Mr. Shawn O'Neil Chief Commercial Officer(age: 52, pay: $413,930)
  • Is Sight Sciences founder-led company?

    Yes, Sight Sciences is a company led by its founder Mr. Paul Badawi.

  • How many employees does Sight Sciences have?

    As Jul 2024, Sight Sciences employs 214 workers.

  • When Sight Sciences went public?

    Sight Sciences, Inc. is publicly traded company for more then 4 years since IPO on 15 Jul 2021.

  • What is Sight Sciences's official website?

    The official website for Sight Sciences is sightsciences.com.

  • Where are Sight Sciences's headquarters?

    Sight Sciences is headquartered at 4040 Campbell Avenue, Menlo Park, CA.

  • How can i contact Sight Sciences?

    Sight Sciences's mailing address is 4040 Campbell Avenue, Menlo Park, CA and company can be reached via phone at 877 266 1144.

  • What is Sight Sciences stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Sight Sciences in the last 12 months, the avarage price target is $8.33. The average price target represents a 103.74% change from the last price of $4.09.

Sight Sciences company profile:

Sight Sciences, Inc.

sightsciences.com
Exchange:

NASDAQ

Full time employees:

214

Industry:

Medical - Devices

Sector:

Healthcare

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

4040 Campbell Avenue
Menlo Park, CA 94025

CIK: 0001531177
ISIN: US82657M1053
CUSIP: 82657M105